Scientific Poster Session II: Students Research-in-Progress

Students Research in Progress
  Sunday, November 12, 2023
  12:45 PM–02:15 PM

Abstract

Introduction: Semaglutide and tirzepatide demonstrated substantial weight loss in overweight/obese patients in clinical trials. Yet, clinical trials and real-world evidence do not always correlate due to differences in patient characteristics, medication access and adherence. Furthermore, there is limited real-world data particularly for tirzepatide to inform practice.

Research Question or Hypothesis: Compare weight outcomes between semaglutide and tirzepatide treatment in the real-world setting in obese or overweight patients regardless of diabetes diagnoses.

Study Design: Single-center, retrospective, observational cohort study.

Methods: Adults with BMI of at least 27 kg/m2, first prescription of semaglutide or tirzepatide in an outpatient setting between 5/13/2022 and 04/01/2023. Primary outcome is the percentage of weight change from baseline to 6-month follow-up. Descriptive statistics will be utilized to compare baseline characteristics and independent t-tests and chi square tests for outcomes between groups. Multivariable linear regression models in diabetes and non-diabetes population, separately, are used to identify the association between treatment groups and outcomes controlling for potential confounders.

Results: The study included 3001 patients; 51% had diabetes. Baseline proportions with diabetes are similar between groups, although the tirzepatide group was younger than semaglutide group with mean (SD) age of 48.3 (11.8) vs. 51.9 (13.2) years, respectively (p <0.001). Baseline weight of tirzepatide was higher with mean of 117.0 (28.0) vs. 113.5 (27.0) kg, respectively, (p= 0.003). More semaglutide patients (56.8%) were prescribed other GLP1s at baseline than tizepatide patients (48.6%), p=0.005. Mean percentage of body weight loss in the tirzepatide group was higher than the semaglutide group (5.3% vs. 2.7%; p=0.005).

Conclusion: Initial descriptive results suggested the effect of tirzepatide on weight loss was significantly higher than semaglutide in the overall population. Multivariable analysis by diabetes status is pending to control for confounding factors.

Presenting Author

Huong Trinh BS
University of Nebraska Medical Center- College of Pharmacy

Authors

Carrie McAdam-Marx MCSI, PhD, RPh
University of Nebraska Medical Center

Anthony Donovan PharmD
University of Nebraska Medical Center